Engineering Fibronectin-Based Binding Proteins by Yeast Surface Display

Department of Biological Engineering, Massachusetts Institute of Technology, Cambridge, Massachusetts, USA
Methods in enzymology (Impact Factor: 2.19). 01/2013; 523:303-26. DOI: 10.1016/B978-0-12-394292-0.00014-X
Source: PubMed

ABSTRACT Yeast surface display (YSD) presents proteins on the surface of yeast through interaction of the agglutinin subunits Aga1p and Aga2p. The human 10th type III fibronectin (Fn3) is a small, 10-kDa protein domain that maintains its native fold without disulfide bonds. A YSD library of Fn3s has been engineered with a loop amino acid composition similar to that of human antibody complementarity-determining region heavy chain loop 3 (CDR-H3) and varying loop lengths, which has been shown to improve binding ability. There are many advantages of using these small, stable domains that maintain binding capabilities similar to that of antibodies. Here, we outline a YSD methodology to isolate Fn3 binders to a diverse set of target antigens.

Download full-text


Available from: Seymour de Picciotto, Oct 20, 2014
1 Follower
  • [Show abstract] [Hide abstract]
    ABSTRACT: Perfringolysin O (PFO) is a member of the cholesterol-dependent cytolysin (CDC) family of bacterial pore-forming proteins, which are highly efficient in delivering exogenous proteins to the cytoplasm. However, the indiscriminate and potent cytotoxicity of PFO limits its practical usage as an intracellular delivery system. In this study, we describe the novel design and engineering of a bi-specific, neutralizing antibody against PFO, which targets reversibly attenuated PFO to endocytic compartments via receptor-mediated internalization. This PFO-based system efficiently mediated the endosomal release of a co-targeted gelonin construct with high specificity and minimal toxicity in vitro. Consequently, the therapeutic window of PFO was improved by greater than five orders of magnitude. Our results demonstrating that the activity of pore-forming proteins can be controlled by antibody-mediated neutralization present a novel strategy to utilize these potent membrane-lytic agents as a safe and effective intracellular delivery system.
    Molecular Pharmaceutics 04/2015; 12(6). DOI:10.1021/mp500797n · 4.79 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Biotherapeutics are attractive anti-cancer agents due to their high specificity and limited toxicity compared to conventional small molecules. Antibodies are widely used in cancer therapy, either directly or conjugated to a cytotoxic payload. Peptide therapies, though not as prevalent, have been utilized in hormonal therapy and imaging. The limitations associated with unmodified forms of both types of biotherapeutics have led to the design and development of novel structures, which incorporate key features and structures that have improved the molecules' abilities to bind to tumor targets, avoid degradation, and exhibit favorable pharmacokinetics. In this review, we highlight the current status of monoclonal antibodies and peptides, and provide a perspective on the future of biotherapeutics using novel constructs. © 2015, The American College of Clinical Pharmacology.
    The Journal of Clinical Pharmacology 03/2015; 55 Suppl 3(S3):S4-S20. DOI:10.1002/jcph.407 · 2.47 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: The review outlines progress and problems in the design of non-natural antibodies for clinical applications over the past 10-15 years. The modular structure of natural antibodies and approaches to its targeted modifications and combination with other structural elements and effector molecules are considered. The review covers modern methods for immunoglobulin engineering and promising strategies for the creation and applications of monoclonal antibodies, their derivatives and analogues, including abzymes and scaffolds, oriented to the use in the diagnosis and targeted therapy of cancer and other socially significant diseases. The bibliography includes 225 references.
    Russian Chemical Reviews 01/2015; 84(1):1-26. DOI:10.1070/RCR4459 · 2.58 Impact Factor